EGFR and medullary thyroid gland carcinoma: Vandetanib, an approved EGFR inhibitor for medullary thyroid cancer, targets EGFR, VEGFR, and RET, offering broad efficacy, but is limited by adverse effects like diarrhea, rash, nausea, hypertension, and QT prolongation.